Trevi Therapeutics (TRVI) Equity Average (2018 - 2026)

Trevi Therapeutics has reported Equity Average for 9 years, with the latest figure at $177.7 million in Q1 2026.

• For the quarter ending Q1 2026, Equity Average rose 78.49% year-over-year to $177.7 million; the trailing twelve-month figure through Mar 2026 stood at $177.7 million (up 78.49% YoY), and the FY2025 full-year result was $141.4 million, up 55.27% from the prior year.
• Equity Average for Q1 2026 stood at $177.7 million, down from $186.5 million in the prior quarter.
• The five-year high for Equity Average was $194.1 million in Q3 2025, with the low at $13.8 million in Q1 2022.
• Average Equity Average over 5 years is $101.2 million, with a median of $92.3 million recorded in 2023.
• Peak annual rise in Equity Average reached 663.88% in 2022, while the deepest fall reached 45.97% in 2022.
• Tracing TRVI's Equity Average over 5 years: stood at $108.7 million in 2022, then retreated by 20.8% to $86.1 million in 2023, then retreated by 7.87% to $79.3 million in 2024, then jumped by 135.18% to $186.5 million in 2025, then dropped by 4.73% to $177.7 million in 2026.
• The last three Equity Average figures came in at $177.7 million (Q1 2026), $186.5 million (Q4 2025), and $194.1 million (Q3 2025), per Business Quant data.

Peer Comparison